• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Nov. 4

A development project for a type of meningitis vaccine of Transgene Biotek Ltd here has been cleared by the Institutional Ethical Committee in the US on the completion of Phase III trials in Africa.

The vaccine has been developed in collaboration with JN International Medical Corporation of the US. The product launch was delayed due to differences with the US partner on certain terms of collaboration agreement.

However the differences with JN International have now been cleared.

Meningococcal infection causes high mortality and morbidity. It is endemic in several countries in Africa, posing threat of epidemics in those countries. The product holds great promise in those countries.

Transgene Biotek is making efforts to expedite the commercial launch of this vaccine. It has already short-listed a few companies within and outside India for contract manufacturing of the vaccine.

The company gains by not sharing the revenues or profits generated out of the sales of the vaccine, unlike the earlier terms of agreement having to share those equally with JN International, the company informed the stock exchanges.

More Stories on : New Products & Services | Pharmaceuticals | Health | Andhra Pradesh

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Karnataka Bank in talks for non-life insurance venture

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line